JP2015512877A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512877A5
JP2015512877A5 JP2014557950A JP2014557950A JP2015512877A5 JP 2015512877 A5 JP2015512877 A5 JP 2015512877A5 JP 2014557950 A JP2014557950 A JP 2014557950A JP 2014557950 A JP2014557950 A JP 2014557950A JP 2015512877 A5 JP2015512877 A5 JP 2015512877A5
Authority
JP
Japan
Prior art keywords
seq
cancer
antigen
binding fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014557950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/000167 external-priority patent/WO2013123588A1/en
Publication of JP2015512877A publication Critical patent/JP2015512877A/ja
Publication of JP2015512877A5 publication Critical patent/JP2015512877A5/ja
Pending legal-status Critical Current

Links

JP2014557950A 2012-02-22 2013-02-22 癌を治療するためのクラステリン阻害剤とegfr阻害剤の併用 Pending JP2015512877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601786P 2012-02-22 2012-02-22
US61/601,786 2012-02-22
PCT/CA2013/000167 WO2013123588A1 (en) 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Publications (2)

Publication Number Publication Date
JP2015512877A JP2015512877A (ja) 2015-04-30
JP2015512877A5 true JP2015512877A5 (https=) 2016-04-14

Family

ID=49004878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557950A Pending JP2015512877A (ja) 2012-02-22 2013-02-22 癌を治療するためのクラステリン阻害剤とegfr阻害剤の併用

Country Status (11)

Country Link
US (1) US9822170B2 (https=)
EP (1) EP2817028A4 (https=)
JP (1) JP2015512877A (https=)
CN (1) CN104159611A (https=)
AU (1) AU2013224591A1 (https=)
BR (1) BR112014020756A2 (https=)
CA (1) CA2862739A1 (https=)
EA (1) EA201491568A1 (https=)
MX (1) MX2014010164A (https=)
NZ (1) NZ626742A (https=)
WO (1) WO2013123588A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666585B (zh) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
SG11201606439VA (en) 2014-02-07 2016-09-29 Dong Wha Pharm Co Ltd Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
WO2016098041A1 (en) 2014-12-18 2016-06-23 Saarum Sciences Private Ltd Establishment and use of an in vitro platform for emt
CN105987997B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1荧光定量检测试纸卡
CN105988004B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1胶体金定量检测试纸卡
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
CN113474012B (zh) * 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药(杭州)有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors
US20250108110A1 (en) * 2022-02-07 2025-04-03 Alethia Biotherapeutics Inc. Combination therapy for use in treatment of non-small cell lung cancer
CN117903305B (zh) * 2023-12-05 2024-08-27 南京欧凯生物科技有限公司 针对雌二醇的单克隆抗体、基于其的检测试剂及其应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3933850A1 (de) 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
ES2159529T5 (es) 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6464975B2 (en) 1998-12-11 2002-10-15 The Research Foundation Of State University Of New York Compositions and methods for altering cell migration
KR100768109B1 (ko) 1999-02-26 2007-10-17 더 유니버시티 오브 브리티쉬 콜롬비아 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP1261743A2 (en) 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
US7279294B2 (en) 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002072830A2 (en) 2001-02-09 2002-09-19 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
EP1419252A2 (en) 2001-04-04 2004-05-19 Merrion Research I Limited Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20030134301A1 (en) 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20070082337A1 (en) 2004-01-27 2007-04-12 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1504099A4 (en) 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
AU2003217966A1 (en) 2002-03-07 2003-10-08 Licentia, Ltd. Lymphatic and blood endothelial cell genes
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
JP4717633B2 (ja) 2002-08-21 2011-07-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 癌関連タンパク質を標的とするRNAiプローブ
NZ538288A (en) 2002-08-21 2008-04-30 Univ British Columbia Treatment of melanoma by reduction in clusterin levels
AU2003279084A1 (en) 2002-09-25 2004-04-19 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20050048490A1 (en) 2002-09-26 2005-03-03 Incyte Corp. Proteins associated with cell growth, differentiation, and death
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
EP1603514A4 (en) 2003-01-24 2007-08-22 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR THYROID CANCER AND APPLICATION METHOD
WO2005049806A2 (en) 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
EA008938B1 (ru) 2003-03-28 2007-10-26 Апплайд Резеч Системз Арс Холдинг Н. В. Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004092378A2 (en) 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US20040224914A1 (en) 2003-04-18 2004-11-11 The University Of British Columbia Method for treatment of angiogenic disorders
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
WO2005060457A2 (en) 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
GB0329254D0 (en) 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
RU2390353C2 (ru) * 2004-02-12 2010-05-27 Мерк Патент Гмбх Высококонцентрированные жидкие композиции анти-egfr антител
ITRM20040098A1 (it) 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP1766408A2 (en) 2004-07-09 2007-03-28 Tripath Imaging, Inc. Methods and compositions for the detection of ovarian cancer
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
AU2005291486A1 (en) 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
DK1814595T3 (da) 2004-11-23 2014-03-31 Univ British Columbia Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
EP1841874B1 (en) 2005-01-27 2010-01-06 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
WO2006089586A1 (en) 2005-02-23 2006-08-31 Medizinische Universität Graz Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins
CA2600929A1 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
EP1869222A4 (en) 2005-04-15 2010-01-20 Oncomethylome Sciences S A METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
US7972770B2 (en) 2005-08-16 2011-07-05 Memorial Sloan-Kettering Cancer Center Methods of detection of cancer using peptide profiles
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006291990B2 (en) 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
CA2634072A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
KR100679173B1 (ko) 2006-02-28 2007-02-06 주식회사 바이오인프라 위암 진단용 단백질 마커 및 이를 이용한 진단키트
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2087152B1 (en) 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
GB0703652D0 (en) 2007-02-26 2007-04-04 Univ Bradford Method for the allosteric modulation of beta1 integrin
US8568993B2 (en) 2007-07-02 2013-10-29 Purdue Research Foundation Detection of glycopeptides and glycoproteins for medical diagnostics
WO2009034562A2 (en) 2007-09-11 2009-03-19 Dublin City University A method of assessing lung squamous cell carcinoma status in an individual
US8617877B2 (en) 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
US7923253B2 (en) 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
EP2071336A1 (en) * 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
WO2009093246A2 (en) 2008-01-22 2009-07-30 Compugen Ltd. Novel clusterin derived peptide
WO2009116860A1 (en) 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
KR101110758B1 (ko) 2008-06-02 2012-02-15 경북대학교 산학협력단 뇌졸중 표적용 펩티드 및 이의 용도
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010030980A2 (en) * 2008-09-12 2010-03-18 University Of South Florida Akt and clusterin as biomarkers of chemotherapeutic responsiveness
AU2010237569B2 (en) 2009-04-17 2015-04-02 National Research Council Of Canada Peptide ligands for clusterin and uses thereof
CN102666585B (zh) * 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Similar Documents

Publication Publication Date Title
JP2015512877A5 (https=)
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
JP2020500538A5 (https=)
PE20140133A1 (es) Nuevas proteinas de union a antigenos
JP2008500815A5 (https=)
JP2013522237A5 (https=)
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
ES2430068T3 (es) Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina
JP2013529183A5 (https=)
NZ603972A (en) Anti-fgfr2 antibodies
NZ596274A (en) Blocking anti-dkk-1 antibodies and their uses
JP2009106306A5 (ja) 抗PDGFRα抗体
MX2015014724A (es) Anticuerpos anti-factor de crecimiento endotelial vascular (vegf) y uso de los mismos.
JP2009102444A5 (ja) 二次性骨腫瘍の治療のための抗PDGFRα抗体
JP2014509593A5 (https=)
IL296682B1 (en) Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
PE20121585A1 (es) ANTICUERPOS CONTRA EL ECTODOMINIO DEL RECEPTOR ErbB3 Y SUS USOS
AR086579A1 (es) Proteinas de union a antigeno
JP2017517506A5 (https=)
JP2015522252A5 (https=)
JP2017528476A5 (https=)
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
JP2014530215A5 (https=)
RU2006137060A (ru) Человеческие антитела к рецептору эпидермального фактора роста